Close Menu

NEW YORK – Quidel reported after the close of the market on Wednesday that its first quarter revenues declined 13 percent year over year, primarily driven by difficult year-over year comparable flu test sales and foreign currency headwind.

For the three months ended March 31, revenues rose to $174.7 million from $148 million in Q1 2019, beating analysts' average estimate of $158.1 million.

The San Diego-based firm attributed the revenue increase to growth in the rapid immunoassay business as well as molecular diagnostic and specialized diagnostic solutions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.